

# Heli Malm

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/472169/publications.pdf>

Version: 2024-02-01

28  
papers

1,967  
citations

361413

20  
h-index

501196

28  
g-index

30  
all docs

30  
docs citations

30  
times ranked

1967  
citing authors

#	ARTICLE	IF	CITATIONS
1	Second-generation antipsychotic use during pregnancy and risk of congenital malformations. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 1737-1745.	1.9	16
2	Second-generation antipsychotics and pregnancy complications. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 107-115.	1.9	22
3	Placental transporter-mediated drug interactions and offspring congenital anomalies. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 868-879.	2.4	9
4	Diagnosis and management of individuals with Fetal Valproate Spectrum Disorder; a consensus statement from the European Reference Network for Congenital Malformations and Intellectual Disability. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 180.	2.7	33
5	Serotonin Reuptake Inhibitor Use During Pregnancy—Reply. <i>JAMA Psychiatry</i> , 2017, 74, 539.	11.0	0
6	New Insights into How Serotonin Selective Reuptake Inhibitors Shape the Developing Brain. <i>Birth Defects Research</i> , 2017, 109, 924-932.	1.5	47
7	Dr. Malm et al. reply:. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2016, 55, 726-727.	0.5	0
8	Association of Selective Serotonin Reuptake Inhibitor Exposure During Pregnancy With Speech, Scholastic, and Motor Disorders in Offspring. <i>JAMA Psychiatry</i> , 2016, 73, 1163.	11.0	117
9	Gestational Exposure to Selective Serotonin Reuptake Inhibitors and Offspring Psychiatric Disorders: A National Register-Based Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2016, 55, 359-366.	0.5	170
10	Pregnancy Outcome Following Maternal Exposure to Mirtazapine. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 250-259.	1.4	32
11	Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. <i>BMJ, The</i> , 2015, 350, h1798-h1798.	6.0	152
12	Genetic variants within the serotonin transporter associated with familial risk for major depression. <i>Psychiatry Research</i> , 2015, 228, 170-173.	3.3	13
13	Early pregnancy cerebral venous thrombosis and status epilepticus treated with levetiracetam and lacosamide throughout pregnancy. <i>Reproductive Toxicology</i> , 2015, 57, 204-206.	2.9	25
14	Pregnancy outcome after TNF- $\alpha$ inhibitor therapy during the first trimester: a prospective multicentre cohort study. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 727-739.	2.4	125
15	Pregnancy Complications Following Prenatal Exposure to SSRIs or Maternal Psychiatric Disorders: Results From Population-Based National Register Data. <i>American Journal of Psychiatry</i> , 2015, 172, 1224-1232.	7.2	106
16	Specialized Service Use for Psychiatric and Neurodevelopmental Disorders by Age 14 in Finland. <i>Psychiatric Services</i> , 2014, 65, 367-373.	2.0	26
17	Effects of Maternal Epilepsy and Antiepileptic Drug Use during Pregnancy on Perinatal Health in Offspring: Nationwide, Retrospective Cohort Study in Finland. <i>Drug Safety</i> , 2013, 36, 359-369.	3.2	52
18	Prenatal Exposure to Selective Serotonin Reuptake Inhibitors and Infant Outcome. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 607-614.	2.0	23

#	ARTICLE	IF	CITATIONS
19	Infant and childhood neurodevelopmental outcomes following prenatal exposure to selective serotonin reuptake inhibitors: overview and design of a Finnish Register-Based Study (FinESSI). <i>BMC Psychiatry</i> , 2012, 12, 217.	2.6	19
20	Selective Serotonin Reuptake Inhibitors and Risk for Major Congenital Anomalies. <i>Obstetrics and Gynecology</i> , 2011, 118, 111-120.	2.4	183
21	Selective Serotonin Reuptake Inhibitors and Risk for Major Congenital Anomalies. <i>Obstetrics and Gynecology</i> , 2011, 118, 1420-1421.	2.4	1
22	Nationwide register-based surveillance system on drugs and pregnancy in Finland 1996-2006. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 729-738.	1.9	39
23	Risks associated with in utero and lactation exposure to selective serotonin reuptake inhibitors (SSRIs). <i>Reproductive Toxicology</i> , 2010, 30, 249-260.	2.9	71
24	Evaluation of the Risk of Congenital Cardiovascular Defects Associated With Use of Paroxetine During Pregnancy. <i>American Journal of Psychiatry</i> , 2008, 165, 749-752.	7.2	164
25	Paroxetine and congenital malformations: Meta-Analysis and consideration of potential confounding factors. <i>Clinical Therapeutics</i> , 2007, 29, 918-926.	2.5	214
26	Risks Associated With Selective Serotonin Reuptake Inhibitors in Pregnancy. <i>Obstetrics and Gynecology</i> , 2005, 106, 1289-1296.	2.4	180
27	Prescription of Hazardous Drugs During Pregnancy. <i>Drug Safety</i> , 2004, 27, 899-908.	3.2	50
28	Prescription drugs during pregnancy and lactation—a Finnish register-based study. <i>European Journal of Clinical Pharmacology</i> , 2003, 59, 127-133.	1.9	74